Compare MNDO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDO | LEXX |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 22.7M |
| IPO Year | 2000 | N/A |
| Metric | MNDO | LEXX |
|---|---|---|
| Price | $1.23 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 52.3K | ★ 135.8K |
| Earning Date | 11-12-2025 | 01-09-2026 |
| Dividend Yield | ★ 17.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $19,770,000.00 | $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | $8.71 | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.98 | $0.77 |
| 52 Week High | $2.13 | $2.85 |
| Indicator | MNDO | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 49.84 |
| Support Level | $1.18 | $1.00 |
| Resistance Level | $1.22 | $1.17 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 90.00 | 41.49 |
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.